{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:03:31Z","timestamp":1794258211939,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences","award":["A-12-802-30"],"award-info":[{"award-number":["A-12-802-30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Colorectal cancer (CRC) is the second leading cause of cancer death. Although Regorafenib showed survival benefits in patients with CRC, reports imply the recurrence of malignant phenotype resulting from chemotherapy. Evidence demonstrated that a5\u03b21 integrin plays an important role in the Regorafenib treatment, which, may be led to resistance. In this study, the effects of \/siRNA or\/ and Quercetin loaded DDAB-mPEG-PCLnanoparticles could reverse this resistance phenotype in colon cancer cells in vitro.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Regorafenib-resistant Ls-180 colon cancer cell line was developed by long-term exposure to Regorafenib. Quercetin and Regorafenib were separately encapsulated into mPEG-PCL micelles through the nano-precipitation method and characterized by DLS. Optimized doses of Quercetin and Regorafenib were used for combination therapy of resistant cells followed cytotoxicity study using MTT. Gene expression levels of the \u03b21 subunit of integrin were determined by the real-time method of RT-PCR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Developed Regorafenib resistant LS-180 showed to have Regorafenib IC50 of 38.96\u2009\u00b1\u20091.72 \u00b5M whereas IC50 in non-resistant cells were 8.51\u2009\u00b1\u20090.29 \u00b5M, which meaningful was lower statistically compared to that of a resistant one. The \u03b21 mRNA level of whole \u03b15\u03b21 integrin was significantly higher in the resistant cells compared to those of non-resistant ones. Gene expression levels in each siRNA-loaded nanoparticle and Quercetin-loaded one were lower than that in mock experiments. Finally, when these two types of nanoparticles were used to treat resistant cells, gene expression decrease of integrin indicated a greater effect that could be capable of reverse resistancy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Results of this study demonstrated another confirmation of involving integrins in cancer resistance following chemotherapy using Regorafenib. Also, it indicated how using siRNA targeting integrin could enhance the plant derivatives like Quercetin effects to reverse resistance in vitro.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-022-03787-8","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T09:03:14Z","timestamp":1672131794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combination of Quercetin or\/and siRNA-loaded DDAB-mPEG-PCL hybrid nanoparticles reverse resistance to Regorafenib in colon cancer cells"],"prefix":"10.1186","volume":"22","author":[{"given":"Shabnam","family":"Shahidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kobra","family":"Rostamizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6844-4869","authenticated-orcid":false,"given":"Mojtaba","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keivan","family":"Nedaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ramazani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"issue":"2","key":"3787_CR1","first-page":"89","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89\u2013103.","journal-title":"Prz Gastroenterol"},{"issue":"9","key":"3787_CR2","doi-asserted-by":"publisher","first-page":"djx030","DOI":"10.1093\/jnci\/djx030","volume":"109","author":"A Jemal","year":"2017","unstructured":"Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, Mariotto A, Lake AJ, Wilson R, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975\u20132014, Featuring Survival. J Natl Cancer Inst. 2017;109(9):djx030.","journal-title":"J Natl Cancer Inst"},{"key":"3787_CR3","doi-asserted-by":"publisher","first-page":"110319","DOI":"10.1016\/j.biopha.2020.110319","volume":"128","author":"YC Liu","year":"2020","unstructured":"Liu YC, Tsai JJ, Weng YS, Hsu FT. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. Biomed Pharmacother. 2020;128:110319.","journal-title":"Biomed Pharmacother"},{"issue":"29","key":"3787_CR4","doi-asserted-by":"publisher","first-page":"46678","DOI":"10.18632\/oncotarget.8712","volume":"7","author":"P Ulivi","year":"2016","unstructured":"Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget. 2016;7(29):46678\u201391.","journal-title":"Oncotarget"},{"issue":"4","key":"3787_CR5","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2217\/nnm.12.22","volume":"7","author":"S Vinogradov","year":"2012","unstructured":"Vinogradov S, Wei X. Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine. 2012;7(4):597\u2013615.","journal-title":"Nanomedicine"},{"issue":"4","key":"3787_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/path.5655","volume":"254","author":"N Oshimori","year":"2021","unstructured":"Oshimori N, Guo Y, Taniguchi S. An emerging role for cellular crosstalk in the cancer stem cell niche. J Pathol. 2021;254(4):384\u201394.","journal-title":"J Pathol"},{"key":"3787_CR7","doi-asserted-by":"publisher","first-page":"6392198","DOI":"10.1155\/2018\/6392198","volume":"2018","author":"C Ciardiello","year":"2018","unstructured":"Ciardiello C, Leone A, Budillon A. The Crosstalk between Cancer Stem Cells and Microenvironment Is Critical for Solid Tumor Progression: The Significant Contribution of Extracellular Vesicles. Stem Cells Int. 2018;2018:6392198.","journal-title":"Stem Cells Int"},{"key":"3787_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.oraloncology.2019.07.001","volume":"96","author":"JH Moon","year":"2019","unstructured":"Moon JH, Rho YS, Lee SH, Koo BS, Lee HJ, Do SI, Cho JH, Eun YG, Park MW, Shin HA, et al. Role of integrin beta1 as a biomarker of stemness in head and neck squamous cell carcinoma. Oral Oncol. 2019;96:34\u201341.","journal-title":"Oral Oncol"},{"issue":"3","key":"3787_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","volume":"35","author":"J Cooper","year":"2019","unstructured":"Cooper J, Giancotti FG. Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019;35(3):347\u201367.","journal-title":"Cancer Cell"},{"issue":"3","key":"3787_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrd.2015.10","volume":"15","author":"K Ley","year":"2016","unstructured":"Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discovery. 2016;15(3):173\u201383.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"3787_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tcb.2014.12.006","volume":"25","author":"L Seguin","year":"2015","unstructured":"Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25(4):234\u201340.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"3787_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cancers5010027","volume":"5","author":"F Schaffner","year":"2013","unstructured":"Schaffner F, Ray AM, Dontenwill M. Integrin alpha5beta1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers. 2013;5(1):27\u201347.","journal-title":"Cancers"},{"issue":"4","key":"3787_CR13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00784-013-1088-y","volume":"18","author":"HC Lin","year":"2014","unstructured":"Lin HC, Wu CL, Chen YL, Huang JS, Wong TY, Yuan K. High-level beta1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells. Clin Oral Invest. 2014;18(4):1277\u201384.","journal-title":"Clin Oral Invest"},{"issue":"12","key":"3787_CR14","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/ijms17122037","volume":"17","author":"D Bianconi","year":"2016","unstructured":"Bianconi D, Unseld M, Prager GW. Integrins in the Spotlight of Cancer. Int J Mol Sci. 2016;17(12):2037.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3787_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/nrc2353","volume":"8","author":"CJ Avraamides","year":"2008","unstructured":"Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8(8):604\u201317.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3787_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/medicines5030093","volume":"5","author":"D Tungmunnithum","year":"2018","unstructured":"Tungmunnithum D, Thongboonyou A, Pholboon A, Yangsabai A. Flavonoids and Other Phenolic Compounds from Medicinal Plants for Pharmaceutical and Medical Aspects: An Overview. Medicines. 2018;5(3):93.","journal-title":"Medicines"},{"issue":"20","key":"3787_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/0973-7847.194044","volume":"10","author":"AV Anand David","year":"2016","unstructured":"Anand David AV, Arulmoli R, Parasuraman S. Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid. Pharmacogn Rev. 2016;10(20):84\u20139.","journal-title":"Pharmacogn Rev"},{"key":"3787_CR18","doi-asserted-by":"publisher","first-page":"109604","DOI":"10.1016\/j.biopha.2019.109604","volume":"121","author":"SM Tang","year":"2020","unstructured":"Tang SM, Deng XT, Zhou J, Li QP, Ge XX, Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother. 2020;121:109604.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3787_CR19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.bcp.2013.11.008","volume":"87","author":"HH Cao","year":"2014","unstructured":"Cao HH, Tse AK, Kwan HY, Yu H, Cheng CY, Su T, Fong WF, Yu ZL. Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling. Biochem Pharmacol. 2014;87(3):424\u201334.","journal-title":"Biochem Pharmacol"},{"key":"3787_CR20","doi-asserted-by":"publisher","first-page":"8525679","DOI":"10.1155\/2016\/8525679","volume":"2016","author":"M Sharma","year":"2016","unstructured":"Sharma M, Sharma R, Jain DK. Nanotechnology Based Approaches for Enhancing Oral Bioavailability of Poorly Water Soluble Antihypertensive Drugs. Scientifica. 2016;2016:8525679.","journal-title":"Scientifica"},{"issue":"6","key":"3787_CR21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.apsb.2019.08.003","volume":"9","author":"C Li","year":"2019","unstructured":"Li C, Wang J, Wang Y, Gao H, Wei G, Huang Y, Yu H, Gan Y, Wang Y, Mei L, et al. Recent progress in drug delivery. Acta Pharm Sinica B. 2019;9(6):1145\u201362.","journal-title":"Acta Pharm Sinica B"},{"issue":"3 Pt A","key":"3787_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","volume":"85","author":"K Hadinoto","year":"2013","unstructured":"Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013;85(3 Pt A):427\u201343.","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"3787_CR23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12094-020-02507-3","volume":"23","author":"M Khodaei","year":"2021","unstructured":"Khodaei M, Rostamizadeh K, Taromchi AH, Monirinasab H, Fathi M. DDAB cationic lipid-mPEG, PCL copolymer hybrid nano-carrier synthesis and application for delivery of siRNA targeting IGF-1R into breast cancer cells. Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2021;23(6):1167\u201378.","journal-title":"Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"issue":"2","key":"3787_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/21691401.2017.1307210","volume":"46","author":"A Singh","year":"2018","unstructured":"Singh A, Trivedi P, Jain NK. Advances in siRNA delivery in cancer therapy. Artif cells Nanomed Biotechnol. 2018;46(2):274\u201383.","journal-title":"Artif cells Nanomed Biotechnol"},{"issue":"1","key":"3787_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nano.2008.06.001","volume":"5","author":"D Reischl","year":"2009","unstructured":"Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine. 2009;5(1):8\u201320.","journal-title":"Nanomedicine"},{"issue":"6","key":"3787_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/onc.2016.247","volume":"36","author":"J Tong","year":"2017","unstructured":"Tong J, Tan S, Zou F, Yu J, Zhang L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene. 2017;36(6):787\u201396.","journal-title":"Oncogene"},{"issue":"Suppl 2","key":"3787_CR27","first-page":"501","volume":"4","author":"H Danafar","year":"2014","unstructured":"Danafar H, Davaran S, Rostamizadeh K, Valizadeh H, Hamidi M. Biodegradable m-PEG\/PCL Core-Shell Micelles: Preparation and Characterization as a Sustained Release Formulation for Curcumin. Adv Pharm Bull. 2014;4(Suppl 2):501\u201310.","journal-title":"Adv Pharm Bull"},{"key":"3787_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jddst.2018.08.025","volume":"48","author":"H Monirinasab","year":"2018","unstructured":"Monirinasab H, Asadi H, Rostamizadeh K, Esmaeilzadeh A, Khodaei M, Fathi M. Novel lipid-polymer hybrid nanoparticles for siRNA delivery and IGF-1R gene silencing in breast cancer cells. J Drug Deliv Sci Technol. 2018;48:96\u2013105.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"3787_CR29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/187152010794728639","volume":"10","author":"C Mas-Moruno","year":"2010","unstructured":"Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anti-cancer Agents Med Chem. 2010;10(10):753\u201368.","journal-title":"Anti-cancer Agents Med Chem"},{"issue":"5","key":"3787_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/cancers11050692","volume":"11","author":"E Cruz da Silva","year":"2019","unstructured":"Cruz da Silva E, Dontenwill M, Choulier L, Lehmann M. Role of Integrins in Resistance to Therapies Targeting Growth Factor Receptors in Cancer. Cancers. 2019;11(5):692.","journal-title":"Cancers"},{"issue":"10","key":"3787_CR31","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-13-0011","volume":"73","author":"WS Carbonell","year":"2013","unstructured":"Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013;73(10):3145\u201354.","journal-title":"Cancer Res"},{"issue":"5","key":"3787_CR32","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/jcp.25206","volume":"231","author":"G Mirone","year":"2016","unstructured":"Mirone G, Perna S, Shukla A, Marfe G. Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. J Cell Physiol. 2016;231(5):1097\u2013105.","journal-title":"J Cell Physiol"},{"issue":"2","key":"3787_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ptr.5984","volume":"32","author":"S Javadi","year":"2018","unstructured":"Javadi S, Rostamizadeh K, Hejazi J, Parsa M, Fathi M. Curcumin mediated down-regulation of alphaV beta3 integrin and up-regulation of pyruvate dehydrogenase kinase 4 (PDK4) in Erlotinib resistant SW480 colon cancer cells. Phytother Res. 2018;32(2):355\u201364.","journal-title":"Phytother Res"},{"issue":"2","key":"3787_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/mt.2010.266","volume":"19","author":"Y Huang","year":"2011","unstructured":"Huang Y, Hong J, Zheng S, Ding Y, Guo S, Zhang H, Zhang X, Du Q, Liang Z. Elimination pathways of systemically delivered siRNA. Mol therapy: J Am Soc Gene Therapy. 2011;19(2):381\u20135.","journal-title":"Mol therapy: J Am Soc Gene Therapy"},{"issue":"1","key":"3787_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd3010","volume":"9","author":"AL Jackson","year":"2010","unstructured":"Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discovery. 2010;9(1):57\u201367.","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"3787_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172\u20136.","journal-title":"Nat Biotechnol"},{"issue":"15","key":"3787_CR37","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1002\/anie.201814289","volume":"58","author":"M Zheng","year":"2019","unstructured":"Zheng M, Jiang T, Yang W, Zou Y, Wu H, Liu X, Zhu F, Qian R, Ling D, McDonald K, et al. The siRNAsome: A Cation-Free and Versatile Nanostructure for siRNA and Drug Co-delivery. Angewandte Chemie. 2019;58(15):4938\u201342.","journal-title":"Angewandte Chemie"},{"issue":"1","key":"3787_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s11671-019-2985-z","volume":"14","author":"Y Lu","year":"2019","unstructured":"Lu Y, Zhong L, Jiang Z, Pan H, Zhang Y, Zhu G, Bai L, Tong R, Shi J, Duan X. Cationic micelle-based siRNA delivery for efficient colon cancer gene therapy. Nanoscale Res Lett. 2019;14(1):193.","journal-title":"Nanoscale Res Lett"},{"issue":"1","key":"3787_CR39","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/21691401.2018.1489271","volume":"47","author":"M Hemati","year":"2019","unstructured":"Hemati M, Haghiralsadat F, Yazdian F, Jafari F, Moradi A, Malekpour-Dehkordi Z. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy. Artif Cells Nanomed Biotechnol. 2019;47(1):1295\u2013311.","journal-title":"Artif cells Nanomed Biotechnol"},{"issue":"5","key":"3787_CR40","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.3390\/molecules26051315","volume":"26","author":"SA Almatroodi","year":"2021","unstructured":"Almatroodi SA, Alsahli MA, Almatroudi A, Verma AK, Aloliqi A, Allemailem KS, Khan AA, Rahmani AH. Potential Therapeutic Targets of Quercetin, a Plant Flavonol, and Its Role in the Therapy of Various Types of Cancer through the Modulation of Various Cell Signaling Pathways. Molecules. 2021;26(5):1315.","journal-title":"Molecules"},{"issue":"6","key":"3787_CR41","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/10837450.2020.1740933","volume":"25","author":"M Ersoz","year":"2020","unstructured":"Ersoz M, Erdemir A, Derman S, Arasoglu T, Mansuroglu B. Quercetin-loaded nanoparticles enhance cytotoxicity and antioxidant activity on C6 glioma cells. Pharm Dev Technol. 2020;25(6):757\u201366.","journal-title":"Pharm Dev Technol"},{"issue":"1","key":"3787_CR42","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1080\/10717544.2020.1815897","volume":"27","author":"Z Zhou","year":"2020","unstructured":"Zhou Z. Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care. Drug Delivery. 2020;27(1):1319\u201328.","journal-title":"Drug Delivery"},{"issue":"9","key":"3787_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0308-1","volume":"51","author":"F Fondevila","year":"2019","unstructured":"Fondevila F, Mendez-Blanco C, Fernandez-Palanca P, Gonzalez-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med. 2019;51(9):1\u201315.","journal-title":"Exp Mol Med"},{"key":"3787_CR44","first-page":"282570","volume":"2012","author":"K Sak","year":"2012","unstructured":"Sak K. Chemotherapy and dietary phytochemical agents. Chemother Res Pract. 2012;2012:282570.","journal-title":"Chemother Res Pract"},{"issue":"26","key":"3787_CR45","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.2174\/0929867322666150812145435","volume":"22","author":"AF Brito","year":"2015","unstructured":"Brito AF, Ribeiro M, Abrantes AM, Pires AS, Teixo RJ, Tralhao JG, Botelho MF. Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics? Curr Med Chem. 2015;22(26):3025\u201339.","journal-title":"Curr Med Chem"},{"issue":"5","key":"3787_CR46","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00280-011-1596-x","volume":"68","author":"D Staedler","year":"2011","unstructured":"Staedler D, Idrizi E, Kenzaoui BH, Juillerat-Jeanneret L. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother Pharmacol. 2011;68(5):1161\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3787_CR47","first-page":"61","volume":"32","author":"T Samuel","year":"2012","unstructured":"Samuel T, Fadlalla K, Mosley L, Katkoori V, Turner T, Manne U. Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res. 2012;32(1):61\u201371.","journal-title":"Anticancer Res"},{"issue":"4","key":"3787_CR48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3892\/ol.2012.829","volume":"4","author":"L Chuang-Xin","year":"2012","unstructured":"Chuang-Xin L, Wen-Yu W, Yao C, Xiao-Yan L, Yun Z. Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-kappaB. Oncol Lett. 2012;4(4):775\u20138.","journal-title":"Oncol Lett"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03787-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-022-03787-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03787-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T12:04:29Z","timestamp":1672401869000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-022-03787-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3787"],"URL":"https:\/\/doi.org\/10.1186\/s12906-022-03787-8","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"1 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethical approval was obtained by the Ethical Committee in the Zanjan University of Medical Sciences issued under number IR.ZUMS.REC.1397.384.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}